Milbank LLP has advised Sartorius AG ("Sartorius"), an international leader in laboratory and bioprocessing technologies for the biopharmaceutical industry, on the acquisition of Albumedix Ltd. ("Albumedix") from private investors.
Sartorius will acquire all outstanding shares in Albumedix for approximately £415 million through its French-listed subgroup Sartorius Stedium Biotech. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.
Albumedix, based in Nottingham (UK) and providing best-in-class recombinant albumin-based solutions, will be part of Sartorius’ Bioprocess Solutions Division. Through this acquisition, Sartorius and Albumedix will expand their solution space with complementary technologies and synergetic competencies, to deliver science-enabled solutions for the entire advanced therapy value chain.
The Milbank team was led by Corporate/M&A partners Michael Bernhardt (Frankfurt), Andrej Wolf (London) and Leopold Riedl (Frankfurt, joint lead) and included partners Alexander Rinne (Antitrust, Munich), Andrea Hamilton (Antitrust, London) and Russell Jacobs (Tax, London), special counsels Andrew Callaghan (Tax, London) and Moritz Lichtenegger (Antitrust, Munich), associates Daniel Woods (Corporate/M&A, London), Steffen Post (Corporate/M&A, Frankfurt), Kim Riah (Litigation & Arbitration, Washington, DC), Asolo Bisade (Leveraged Finance/Capital Markets, London) and Cosmos Fung (Tax, London).
